Intravitreous administration has emerged as the dominant route of drug delivery in the Uveitis Drug Market, reflecting its use for direct, high-efficacy dosing in more severe drug-treated cases. By injecting medication directly into the vitreous humor of the eye, intravitreous administration achieves high local drug concentrations while minimising systemic exposure and side effects. This targeted approach is particularly valuable for treating posterior uveitis and panuveitis, where systemic therapies may not achieve adequate drug levels in the eye.

The Uveitis Drug Market is characterised by the dominance of intravitreous administration, which is projected to grow from USD 1.125 billion in 2024 to USD 1.845 billion by 2035. This growth reflects the increasing adoption of intravitreal injections for delivering corticosteroids and biologics directly to the site of inflammation. Additionally, the development of sustained-release implants, such as fluocinolone acetonide implants, is reducing the frequency of injections and improving patient convenience.

The market is also benefiting from technological advancements that enhance the safety and efficacy of intravitreous administration. Improved injection techniques and devices are reducing the risk of complications such as endophthalmitis and retinal detachment. Additionally, the integration of imaging technologies is enabling more precise needle placement and monitoring of treatment response. As the demand for targeted uveitis therapies continues to rise, the Uveitis Drug Market is expected to see sustained growth in intravitreous administration.

People Also Ask

• What is intravitreous administration?
  Intravitreous administration involves injecting medication directly into the vitreous humor of the eye, achieving high local drug concentrations with minimal systemic exposure.

• What are the advantages of intravitreous administration?
  Advantages include targeted drug delivery, reduced systemic side effects, and improved efficacy for posterior uveitis and panuveitis.

Tags: #Intravitreous #UveitisDrug #DrugDelivery #Ophthalmology #IntravitrealInjection #EyeCare